Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Al-Sawaf O, Zhang C, Jin H, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang Y, Fink A, Tausch E, Schneider C, Ritgen M, Kreuzer K, Chyla B, Paulson J, Pallasch C, Frenzel L, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nature Communications 2023, 14: 2147. PMID: 37072421, PMCID: PMC10113251, DOI: 10.1038/s41467-023-37648-w.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicChlorambucilHumansLeukemia, Lymphocytic, Chronic, B-CellTranscriptomeConceptsProgression-free survivalChronic lymphocytic leukemiaUntreated chronic lymphocytic leukemiaLymphocytic leukemiaAssociated with longer progression-free survivalParallel-group phase 3 studyProgression-free survival ratesTreatment of chronic lymphocytic leukemiaLonger progression-free survivalDepth of remissionMedian follow-upPhase 3 studyAssociated with increased expressionLong-term efficacyLong-term outcomesExploratory post hoc analysisPost hoc analysisMRD statusBCL2 inhibitionOverall survivalPrimary endpointSecondary endpointsInflammatory response pathwaysVenetoclax-obinutuzumabFollow-up